About: Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 21 February 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) im Februar 2019 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 2019 (ast) наукова стаття, опублікована в лютому 2019 (uk) scientific article published on 21 February 2019 (en)
publication date	wds:Q64119481-50EEAB25-2CEA-4957-9081-97B23B3BA9EE
publication date	2019-02-21 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q64119481-425677A8-D8C5-4B9B-9C96-A08223AF24EE
language of work or name	English
cites work	wds:Q64119481-0C6B3D78-6B31-430C-A9D5-A8A313BCC8C7 wds:Q64119481-23148FC6-A089-427D-80A7-0FB7FBD95E3E wds:Q64119481-30EBF094-6D8B-4E45-853D-DBF8AA2EC9CB wds:Q64119481-33A2F365-F100-41D7-A660-9261970ED09E wds:Q64119481-4DFE8723-63F4-4101-B073-3541EBD998A9 wds:Q64119481-4EF225AB-AD6B-482D-BDDC-CA82FB81AE2B wds:Q64119481-5150C88E-9574-4D88-B1D3-45289C118714 wds:Q64119481-59A52EA2-B614-44EF-B2CC-0DCDDF27EF2A wds:Q64119481-66876CED-4DDB-4277-A7AF-CFEBEA40EE51 wds:Q64119481-69952606-D594-41F5-8FB7-E16DB3B0EB02 wds:Q64119481-7A240FC2-8C99-45B8-826D-BEBE849DA32A wds:Q64119481-8C2B4ADB-DC16-48F9-A072-C0CEBD2D16B1 wds:Q64119481-8F895B59-42AB-4EBD-BB32-BBCC63093705 wds:Q64119481-951179A5-F3DF-40FF-84A2-75C2213416AC wds:Q64119481-A0B3EDAB-D45D-4CDD-94B9-AA2D835DDAD1 wds:Q64119481-A4A37134-F87B-4A76-B3D8-9F7A30FD551C wds:Q64119481-B0D88721-3381-45B1-91EB-65ADCF28F009 wds:Q64119481-C03693D7-4098-43B6-BE7D-60FA21BE4D50 wds:Q64119481-C3A1FC8D-108C-4B65-AA3F-FD7B54B02D30 wds:Q64119481-E195DFD1-3938-4CF8-B386-AEABD47FCFF8 wds:Q64119481-ECD96381-2AF7-4F29-8A28-8450278AE8A9 wds:Q64119481-F024D244-7F95-4DF7-8FA7-3076EDDB5D5F wds:Q64119481-F49331F3-39C5-4AD7-AFFA-CD9D58825FDC wds:Q64119481-F652220B-98FD-4578-8E3B-DD46F22043B2 wds:Q64119481-FC2DA03F-FC86-4633-845F-E84C862E76D7 wds:Q64119481-FD2CA07F-77F4-497A-8802-AE1E05BE731C wds:Q64119481-FEA6865D-D035-45E2-B2EE-F8D1FACA7C2B
cites work	Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study Basal insulin requirement is ~30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump 10-year follow-up of intensive glucose control in type 2 diabetes Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1 Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes Seasonal fluctuations of glycated hemoglobin levels in Japanese diabetic patients Frequent hypoglycemia among elderly patients with poor glycemic control Minimizing Hypoglycemia in Diabetes Altered Hierarchy of Protective Responses Against Severe Hypoglycemia in Normal Aging in Healthy Men Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month e New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes management and daily functioning burden of non-severe hypoglycemia in Japanese people treated with insulin 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-mo Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward? Difference of seasonal variation between glycated albumin and glycated haemoglobin
author name string	wds:Q64119481-5912CA0B-32D7-4059-ABF5-CF3ABBA5665C wds:Q64119481-8E1F4F16-223E-45CF-98D6-0F36B25D47BE wds:Q64119481-950426BF-C1D8-418B-B2D8-B5FD6A9A062A wds:Q64119481-AFC7FDA4-FF1C-4351-A3B7-C1818409F58B wds:Q64119481-EEB34AF5-0A73-444D-ADF6-04DF36C3F402
author name string	Hiroshi Itoh Masami Tanaka Yoshifumi Saisho Shu Meguro Kazutoshi Sugiyama
rdfs:label	Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis (en) Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis (nl)
skos:prefLabel	Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis (en) Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis (nl)
name	Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis (en) Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis (nl)
author	wds:Q64119481-59D3F21F-67A8-435B-A7BF-AD950928523E
author	Junichiro Irie
title	wds:Q64119481-AA532C31-E43B-42AC-8707-A84C62312CDC
title	Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis (en)
page(s)	wds:Q64119481-5CE05110-670B-405A-852E-10895CD54DC9
page(s)	e01257
instance of	wds:Q64119481-5BD71072-409F-4E62-84DA-CC290DDF085F
instance of	scholarly article
main subject	wds:Q64119481-4A6E7FB3-5EBD-410E-BD95-86505858E2C3 wds:Q64119481-9200A44E-FA25-4A3A-8321-49F8303FF1C3
main subject	insulin glargine type 2 diabetes
PubMed ID	wds:Q64119481-BAE4B87C-57C4-4802-9792-5B1B1E631F02
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30886921
PubMed ID	30886921
published in	wds:Q64119481-E65E30C8-9686-4EAB-BD0B-ADC00FFB47E5
published in	Heliyon
issue	wds:Q64119481-E788BEB5-2F92-4981-A249-90836A973B13
volume	wds:Q64119481-4750A662-9DE2-4DF3-9D51-43D02EDDE02E
issue	2

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 182 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software